A股異動 | 未來股份(600532.SH)漲近6% 子公司擬收購Fullerton Healthcare100%股權
格隆匯12月24日丨未來股份(600532.SH)漲近6%,報18.99元,總市值98億元。未來股份公吿,全資子公司未郎醫療有意向以自身或公司控制的關聯方作為收購主體,以現金形式通過直接或間接的方式收購Fullerton Healthcare Corporation Limited100%的普通股股權,預計全部標的股權的價格約7億-8億新加坡元,本次交易可能構成重大資產重組。Fullerton Healthcare Corporation Limited於2010年成立於新加坡,是一家綜合醫療服務平台。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.